FHTX
Foghorn Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.87
+1.08%Oct 1, 2026, 11:40 UTC
Foghorn Therapeutics and Eli Lilly dissolved their cancer-drug partnership and plan no future collaborations.
Source:Oct 1, 2026, 11:00 UTC
Foghorn Therapeutics and Eli Lilly decided not to advance the FHD-909 program and the selective SMARCA2 degrader program, and Foghorn will cut about 40% of its workforce while prioritizing its wholly owned pipeline, extending its cash runway into the second half of 2029.
Source:Aug 6, 2026, 00:00 UTC
Foghorn Therapeutics Inc. reported its Q2 2026 financial results, with collaboration revenue of $16.1 million, a net loss of $7.2 million, and diluted EPS of -$0.10.
Source: